Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06383208
Status:
RECRUITING
Last Update Posted:
2024-04-25
First Post:
2024-04-21
Brief Title:
Cardiovascular-Renal Adverse Prognosis Assessment System for Coronary Heart Disease With Chronic Kidney Disease Based on Metabolomics
Sponsor:
China-Japan Friendship Hospital
Organization:
China-Japan Friendship Hospital
Study Overview
Official Title:
Cardiovascular-Renal Adverse oUtcome rIsk aSsessment systEm for Coronary Heart Disease Complicated With Chronic Kidney Disease Based on Targeted Lipid METabolomics
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CRUISE-MET
Brief Summary:
Coronary heart disease CHD combined with chronic kidney disease CKD affects a substantial portion of the population and carries a significant disease burden often leading to poor outcomes Despite efforts to strictly control traditional risk factors the efficacy in improving outcomes for patients with both CHD and CKD has been limited Recent advancements in lipid metabolism research have identified new lipid metabolites associated with the occurrence and prognosis of CHD and CKD Our preliminary trial has shown that levels of certain lipid metabolites such as Cer181160 HexCer181160 and PI180181 are notably elevated in patients with CHD and reduced kidney function compared to those with relatively normal kidney function This suggests that dysregulation of these non-traditional lipid metabolites may contribute to residual risk for adverse outcomes in these patients
Furthermore the emerging concept of cardiovascular-kidney-metabolic syndrome and the availability of new treatment options highlight the urgent need for a risk stratification tool tailored to modern management strategies and treatment goals to guide preventive measures effectively To address this we propose to conduct a prospective cohort study focusing on CHD combined with CKD This study aims to comprehensively understand the clinical characteristics diagnosis treatment status and cardiovascular-kidney prognosis in these patients Through advanced metabolomics analysis we seek to identify lipid metabolism profiles and non-traditional lipid metabolites associated with the progression of coronary artery disease in CHD-CKD patients Leveraging clinical databases and metabolomics data we will develop a robust risk prediction model for adverse cardiovascular-kidney outcomes providing valuable guidance for clinical diagnosis treatment decisions and ultimately improving patient prognosis
Furthermore the emerging concept of cardiovascular-kidney-metabolic syndrome and the availability of new treatment options highlight the urgent need for a risk stratification tool tailored to modern management strategies and treatment goals to guide preventive measures effectively To address this we propose to conduct a prospective cohort study focusing on CHD combined with CKD This study aims to comprehensively understand the clinical characteristics diagnosis treatment status and cardiovascular-kidney prognosis in these patients Through advanced metabolomics analysis we seek to identify lipid metabolism profiles and non-traditional lipid metabolites associated with the progression of coronary artery disease in CHD-CKD patients Leveraging clinical databases and metabolomics data we will develop a robust risk prediction model for adverse cardiovascular-kidney outcomes providing valuable guidance for clinical diagnosis treatment decisions and ultimately improving patient prognosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None